DDInter708 DDInter1016
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Ezogabine {u} (Compound) resembles {v} (Compound) Flupirtine
Ezogabine {u} (Compound) binds {v} (Gene) UGT1A1
Ezogabine {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Openers
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ezogabine (Compound) resembles Flupirtine (Compound)
Ezogabine (Compound) binds UGT1A1 (Gene)
Ezogabine (Compound) is included by Potassium Channel Openers (Pharmacologic Class)
Ezogabine (Compound) causes Ill-defined disorder (Side Effect)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezogabine may lead to a major life threatening interaction when taken with Nilotinib
Ezogabine may lead to a major life threatening interaction when taken with Crizotinib